Akt activation. Dual inhibition of EGFR and IGF1R inhibits cSCCHN cell growth more effectively than either inhibitor alone, suggesting that combination therapy with both inhibitors may be a promising therapeutic strategy for cSCCHN.
Objective: Tobacco metabolites have been shown to be markers of tobacco exposure as well as markers of lung cancer risk. To this point, tobacco metabolites have not been studied in head and neck squamous cell carcinoma (HNSCC) . We seek to study tobacco metabolites in smokers with (subjects) and without (controls) HNSCC.
Method:
Smokers with head and neck cancer were enrolled after they completed a detailed smoking history questionnaire. Urine samples were collected in standard fashion. Controls consisted of smokers without HNSCC. Urinary levels of total 1-hydroxypyrene (1-HOP) and total 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) and N′-nitrosonornicotine (NNN) were assayed using high performance liquid chromatography (HPLC).
Results:
In this pilot study, NNN data were available in 27 subjects, NNAL in 19 subjects, and 1-HOP in 18 subjects. Control matching for NNN was done with a 1:1 ratio. Controls were matched on cigarettes per day in a 3:1 ratio for NNAL and 1-HOP to increase power. T test was used to compare study subjects with controls. Mean levels for subjects (S) and controls (C) were: NNN [S:0.12 pmol/mL, C:0.06 pmol/mL (P = .06)], NNAL [S:1.53 pmol/mL, C:1.25 pmol/mL (P = .
3)], and 1-HOP [S:1.88 pmol/mL, C:0.84 pmol/mL (P = .001)], respectively.
Conclusion: 1) Smokers with HNSCC have higher urinary 1-HOP (significant) and NNN (near significant) compared with matched controls. 2) The data suggest smokers who develop HNSCC process carcinogens differently than smokers without HNSCC. 3) This data is a first step toward understanding why some smokers develop carcinoma while others do not.
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Endoscopic Surgery and iMRT Are Effective in Recurrent NPC
Ming-Yuan Chen, MD, PhD (presenter); Rou Jiang Objective: Salvage surgery and radiotherapy showed positive and similar survival outcomes in rT1/2 local recurrent nasopharyngeal carcinoma (rNPC) but no curative value in rT3/4 ones in the past. We will evaluate new techniques such as endoscopic surgery and intensity-modulated radiotherapy (IMRT) to compare with conventional radiotherapy (CRT) and chemotherapy in rNPC.
Method:
We did a retrospective review of 493 rNPC patients from January 2000 to December 2009. IMRT, CRT, and/or chemotherapy were suitable to all rT stage cases, but endoscopic surgery was applied to rT1 and some selected rT2/T3 cases. The 5-year overall survival rate (OS) and other oncological outcomes were summarized.
Results: Among 493 cases, 120, 82, 132, and 159 were restaged in rT1N0M0, rT2N0M0, rT3N0M0, and rT4N0M0 according to AJCC/UICC 2002 TNM stage system. The 5-year OS was 73.0%, 37.0%, 17.3%, and 16.5% in rT1, rT2, rT3, and rT4 patients (P < .05). Adjusted for rT stages, the salvage surgery and IMRT showed a better survival curve than conventional radiotherapy and chemotherapy (P < .01). In rT1 patients, the 5-year OS of patients who received salvage endoscopic surgery was better than that of ones who received IMRT (89.3% vs 69.0%, P < .01). Cox analysis showed that age, stage, and salvage treatment were significant independent predictors for OS.
Conclusion:
Although patients in the earlier rT stage showed better survival than ones in the advanced rT stage, new salvage treatments based on endoscopic surgery and IMRT benefited all rT stage rNPC compared with CRT and chemotherapy. Futhermore, salvage endoscopic surgery may be a more promising option than IMRT in rT1 patients.
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Extracapsular Extension in lymph Node Metastasis from HPV-Associated Squamous Cell Carcinoma of the Oropharynx
Ian Smith, MD (presenter); Elizabeth Rosenblatt; Giuseppe Sanguineti; Justin A. Bishop; Jeremy D. Richmon, MD; Sara Pai, MD, PhD Objective: Oropharyngeal cancer understanding has been greatly advanced with the discovery of the role of HPV. Nonsurgical approaches that utilize chemotherapy-radiotherapy have become common treatment. However, upfront surgery has recently gained momentum with the introduction of transoral approaches (laser/robotic). These approaches have been applied to all stages with excellent results.
Method: Determine the rate of extracapsular extension (ECE) in all patients with HPV+ oropharyngeal cancer (70 patients) treated with a neck dissection at our institution since pathologic HPV testing was first instituted (2006 to present).
Results:
We looked at clinical features such as: T stage, primary site, clinical N-stage, node count, staging, sex, race, smoking, and features on preoperative imaging (cystic?, matted?, multiple nodes, number of nodes, and laterality). Of note we found a relationship between patients with lymph nodes >4 cm on pretreatment imaging having a statistically significant (P = .019) higher rate of extracapsular extension 47% (4cm). Clinical nodal stages related to rates of extracapsular extension with N1 (28.5% ECE), N2A (50% ECE), N2B (68.9% ECE), and N2C (75% ECE). We also noted that multiple nodes on final pathology also were associated with ECE. In
